SAB Biotherapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview

SAB Biotherapeutics

05/08/2025 24:35

SAB Biotherapeutics Inc SABS.OQ SABS.O is expected to  show a fall in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for SAB Biotherapeutics Inc is for a loss of 80 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for SAB Biotherapeutics Inc is $11.50, about 80.2% above its last closing price of $2.28

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-1.07
-1.03
-0.56
Beat
45.6
Dec. 31 2025
-1.16
-1.23
Missed
-5.3
Sep. 30 2024
-1.09
-1.09
-1.12
Missed
-2.8​
Jun. 30 2024
-1.12
-1.13
-0.79
Beat
30.1
​​Mar. 31 2024
-0.96
-0.96
-0.60
Beat
37.5
Dec. 31 2023
-0.64
-0.62
-3.38
Missed
-445.2​
Sep. 30 2023
-1.16
-1.17
-1.00
Beat
14.3
Jun. 30 2023
-1.48
-1.45
-1.40
Beat
3.4

This summary was machine generated August 4 at 23:35 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)